You are viewing the site in preview mode

Skip to main content


Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

Fig. 1

Representative endoscopic and histologic findings before and after vedolizumab therapy in patients who had good response. (a, b) Endoscopic presentations before vedolizumab therapy showing diffuse erythema and focal punctate mucosal ulcerations. (c, d) Endoscopic presentations from the same patients after vedolizumab therapy showing normal mucosa. (e) Before vedolizumab therapy, chronic active colitis with cryptitis and crypt abscesses in the background of lamina propria expansion by lymphoplasmacytic infiltration, basal lymphoplasmacytosis, and architecture distortion. (f) After vedolizumab therapy, chronic colitis with architecture distortion and glandular dropout without active colitis. Chronic infiltrates in the lamina propria were markedly reduced to almost normal

Back to article page